Angiopoietins 1 and 2 and Tie-2 receptor expression in human ductal breast disease

Histopathology

Volumn 59, Issue 2, 2011, Pages 256-263

  Staton, Carolyn A ^a   Hoh, Leslie ^a   Baldwin, Alice ^a   Shaw, Lucy ^a   Globe, Jenny ^a   Cross, Simon S ^a   Reed, Malcolm W ^a   Brown, Nicola J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Angiopoietins; Breast cancer; Tie 2; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GROWTH; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HYPERPLASIA; PRECANCEROUS CONDITIONS; RECEPTOR, TIE-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052239423     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03920.x     Document Type: Article

References (35)

1. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann. Intern. Med. 2005; 143; 446-457.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995; 1; 27-31.
3. Teo NB, Soker BS, Jarvis C, Martin L, Sloane JP, Holcombe C. Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast. Anticancer Res. 2002; 22; 2601-2672.
4. Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MW. The angiogenic switch occurs at the adenoma stage of the adenoma-carcinoma sequence in colorectal cancer. Gut 2007; 56; 1426-1432.
5. Bluff JE, Menakuru SR, Cross S et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br. J. Cancer 2009; 101; 666-672.
6. Menakuru SR, Brown NJ, Staton CA, Reed MWR. Angiogenesis in premalignant conditions. Br. J. Cancer 2008; 99; 1961-1966.
7. Ferrara N, Davis-Smyth T. The biology of VEGF. Endocr. Rev. 1997; 18; 4-25.
8. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N. Correlation between vascular endothelial growth factor, angiogenesis and tumor-associate macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002; 440; 583-588.
9. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp. Cell Res. 2006; 312; 630-641.
10. Gamble JR, Drew J, Trezise L et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 2000; 87; 603-607.
11. Suri C, Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87; 1171-1180.
12. Thurston G, Suri C, Smith K et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286; 2511-2514.
13. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277; 55-60.
14. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006; 3; e46.
15. Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur. J. Surg. Oncol. 2007; 33; 7-15.
16. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J. Pathol. 2004; 204; 1-10.
17. Osada H, Tokunaga T, Hatanaka H et al. Gene expression of angiogenesis related factors in glioma. Int. J. Oncol. 2001; 18; 305-309.
18. Moon WS, Rhyu KH, Kang MJ et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol. 2003; 16; 552-557.
19. Sun XD, Liu XE, Wu JM, Cai XJ, Mou YP, Li JD. Expression and significance of angiopoietin-2 in gastric cancer. World J. Gastroenterol. 2004; 10; 1382-1385.
20. Zhang L, Yang N, Park JW et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003; 63; 3403-3412.
21. Currie MJ, Gunningham SP, Han C et al. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodelling. Clin. Cancer Res. 2001; 7; 918-927.
22. Sfiligoi C, de Luca A, Cascone I et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer 2003; 103; 466-474.
23. Tsutsui S, Inoue H, Yasuda K et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res. Treat. 2006; 98; 261-266.
24. De Hoon MJ, Imoto S, Nolan J et al. Open source clustering software. Bioinformatics 2004; 20; 1453-1454.
25. Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 1998; 95; 14863-14868.
26. Saldanha AJ. Java Treeview - extensible visualization of microarray data. Bioinformatics 2004; 20; 3246-3248.
27. Blows FM, Driver KE, Schmidt MK et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 2010; 7; e1000279.
28. Tanaka S, Sugimachi K, Yamashita Y et al. Angiogenic switch as a molecular target of malignant tumors. J. Gastroenterol. 2003; 38; 93-97.
29. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002; 131; S135-S141.
30. Hayes AJ, Huang WQ, Yu J et al. Expression and function of angiopoietin-1 in breast cancer. Br. J. Cancer 2000; 83; 1154-1160.
31. Rmali KA, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. Angiopoietins lack of prognostic significance in ductal mammary carcinoma. Int. Semin. Surg. Oncol. 2007; 4; 6.
32. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 2005; 14; 425-431.
33. Kashiwagi S, Yashiro M, Takashima T et al. Significance of E-cadherin expression in triple-negative breast cancer. Br. J. Cancer 2010; 103; 249-255.
34. Imanishi Y, Hu B, Jarzynka MJ et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007; 67; 4254-4263.
35. Mochizuki N. Vascular integrity mediated by vascular endothelial cadherin and regulated by sphingosine 1-phosphate and angiopoietin-1. Circ. J. 2009; 73; 2183-2191.